Shimura Masaru, Nishimata Shigeo, Saito Naoko, Tsutsumi Norito, Suzuki Shinji, Morishima Yasuyuki, Kashiwagi Yasuyo, Numabe Hironao, Kawashima Hisashi
Department of Pediatrics.
Clinical Genetics Center, Tokyo Medical University, Tokyo, Japan.
J Pediatr Hematol Oncol. 2019 Jul;41(5):e325-e328. doi: 10.1097/MPH.0000000000001301.
Therapeutic phlebotomy is recommended for treating hereditary hemochromatosis. However, the procedure and its efficacy for children remain unclear. We describe a young female patient with ferroportin disease, which was confirmed from excess iron deposition within hepatocytes and by identifying a heterozygous variant p.Cys326Phe in SLC40A1. She had been followed without phlebotomy. Liver histology at age 13 years revealed iron deposition progression. Phlebotomy was initiated and her iron markers and imaging findings improved without severe adverse effects. Therapeutic phlebotomy for children is effective and well-tolerated and should be considered as early as possible after a hemochromatosis diagnosis.
推荐采用治疗性放血疗法治疗遗传性血色素沉着症。然而,该疗法及其对儿童的疗效仍不明确。我们描述了一名患有铁转运蛋白病的年轻女性患者,通过肝细胞内铁沉积过多以及在SLC40A1基因中鉴定出杂合变异p.Cys326Phe得以确诊。她在未进行放血治疗的情况下接受随访。13岁时的肝脏组织学检查显示铁沉积进展。随后开始进行放血治疗,她的铁指标和影像学检查结果得到改善,且未出现严重不良反应。儿童治疗性放血疗法有效且耐受性良好,在血色素沉着症诊断后应尽早考虑使用。